RPE-specific mice suitable for gene activation and inactivation

Article

A tetracycline-inducible Cre mouse line created specifically to study the retinal pigment epithelium (RPE) is suitable for Cre/lox-based gene activation and inactivation in adult RPE, which makes the mice suitable for long-term studies requiring conditional gene targeting.

A tetracycline-inducible Cre mouse line created specifically to study the retinal pigment epithelium (RPE) is suitable for Cre/lox-based gene activation and inactivation in adult RPE, which makes the mice suitable for long-term studies requiring conditional gene targeting.

According to researchers in the Department of Ophthalmology, the Second Affiliated Hospital of Nanchang University, Nanchang, China, and the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA, intravitreal Dox delivery can effectively induce productive Cre-mediated recombination in this mouse line, with no apparent Dox or Cre toxicity. The mice have been used for several conditional gene-targeting studies.

The researchers conducted an analysis of Cre expression and function in double transgenic mice that were derived from inducible RPE-specific Cre and Cre-activatable ROSA26 lacZ reporter mice. Cre expression was induced by intravitreal doxycycline. The researchers used reverse transcription–polymerase chain reaction (RT-PCR), immunoblotting, immunostaining and in situ enzymatic assay for β-galactosidase to examine Cre expression and function, and electroretinography and morphometry to examine retinal integrity. They found that Cre expression was significantly elevated by the intravitreal doxycycline injection, resulting in productive Cre-mediated recombination in about 60% of the RPE cells in these mice, with no effect on the integrity of the retina.

"Our work provides a way for more effective use of this mouse line," the researchers wrote. "However, other approaches capable of increasing the efficiency of productive Cre-mediated recombination may permit equal or better utilization of this mouse line. The end-users should explore these avenues that fit their individual experimental goals."

To read the entire study visit the journal Molecular Vision.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.